Molbio Diagnostics IPO Price: ₹768 to ₹807 per share
IPO Dates: 10 Aug to 12 Aug, 2026
Company Overview
Incorporated in October 2000, Molbio Diagnostics Limited is a global point-of-care (POC) molecular diagnostics company engaged in the research, development, manufacturing, and commercialization of rapid diagnostic solutions for infectious and non-communicable diseases.
The company has developed its proprietary ‘Truenat’ platform, a portable, battery-operated PCR-based molecular diagnostics system designed for resource-limited settings, offering accurate test results within an hour
Business Operations
Molbio offers molecular testing solutions for over 30 diseases through 43 diagnostic assays, including tuberculosis (TB), COVID-19, HIV, Hepatitis B & C, and HPV.
The company also provides radiology, digital pathology, and breast health screening solutions through its subsidiaries and strategic collaborations, while continuously expanding its diagnostics product pipeline through strong in-house R&D capabilities.
Manufacturing & Global Presence
The company operates six manufacturing facilities across India and serves customers in over 90 countries.
Customer Base
The company serves government health programs, diagnostic laboratories, hospitals, and international healthcare organizations.
Workforce
As of March 31, 2026, the company employed 1,225 permanent employees across research & development, manufacturing, quality assurance, sales, finance, and corporate functions.
Market Position
Backed by a strong portfolio of patents, global certifications, and strategic acquisitions, Molbio has established itself as a leading innovator in molecular diagnostics.
Key Strengths
- Proprietary Truenat platform with WHO-endorsed TB molecular diagnostic technology
- .Strong R&D capabilities supported by an extensive global patent portfolio.
- Scalable business model with recurring revenues from diagnostic test kits.
- Global presence across 90+ countries with strong government and institutional customer base.
- Strategic acquisitions and collaborations expanding healthcare diagnostics portfolio.
- Experienced management team with deep expertise in molecular diagnostics and healthcare innovation.
Bidding Starts In
Molbio Diagnostics IPO Specifics:
| IPO Date | 10 to 12 Aug, 2026 |
| Listing Date | Mon, Aug 17, 2026 |
| Face Value | ₹1 per share |
| Price Band | ₹768 to ₹807 |
| Lot Size | 18 Shares |
| Sale Type | Fresh capital cum OFS |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Employee Discount | ₹76.00 |
| Total Issue Size |
1,16,46,246 shares (agg. up to ₹940 Cr) |
| Fresh Issue |
24,80,246 shares (agg. up to ₹200 Cr) |
| Offer for Sale |
91,66,000 shares of ₹1 (agg. up to ₹740 Cr) |
| Share Holding Pre Issue | 11,27,59,750 shares |
| Share Holding Post Issue | 11,52,39,996 shares |
Molbio Diagnostics IPO Timetable (Important Dates)
| Event | Date |
|---|---|
| IPO Open | Mon, Aug 10, 2026 |
| IPO Close | Wed, Aug 12, 2026 |
| Allotment | Thu, Aug 13, 2026 |
| Refund | Fri, Aug 14, 2026 |
| Credit of Shares | Fri, Aug 14, 2026 |
| Listing | Mon, Aug 17, 2026 |
Molbio Diagnostics IPO Lot Size
Investors can bid for a minimum of 18 shares and in multiples thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 18 | ₹14,526 |
| Retail (Max) | 13 | 234 | ₹1,88,838 |
| S-HNI (Min) | 14 | 252 | ₹2,03,364 |
| S-HNI (Max) | 68 | 1,224 | ₹9,87,768 |
| B-HNI (Min) | 69 | 1,242 | ₹10,02,294 |
Molbio Diagnostics IPO Reservation
| Investor Category | Shares |
|---|---|
| QIB | Not more than 50% of the Net Offer |
| Retail | Not less than 35% of the Net Offer |
| NII | Not less than 15% of the Net Offer |
Molbio Diagnostics IPO Financial Information
| Particulars (₹ Cr) | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 2,148.42 | 1,461.56 | 1,221.06 |
| Total Income | 1,455.17 | 1,027.94 | 840.66 |
| Profit After Tax | 164.14 | 138.58 | 83.54 |
| EBITDA | 328.24 | 256.64 | 185.09 |
| Net Worth | 1,144.68 | 952.95 | 807.94 |
| Reserves & Surplus | 1,148.84 | 990.84 | 845.48 |
| Total Borrowing | 412.64 | 123.16 | 174.58 |
Key Performance Indicator -Molbio Diagnostics IPO
| KPI | Value |
|---|---|
| ROE | 15.59% |
| ROCE | 17.55% |
| RoNW | 14.55% |
| PAT Margin | 11.28% |
| EBITDA Margin | 22.56% |
| NAV | 101.51 |
| Price to Book value | 9.55* |
| EPS (₹) | 14.56 |
| P/E(x) | 55.43 |
| Market Cap | ₹9099.71Cr. |
Prospectus Links:
Prospectus: Official documents that provide detailed information about the IPO and the company.
Kaashika is a social media strategist and financial content creator at Lakshmishree. She specialises in simplifying complex IPO and stock market concepts into clear, easy-to-understand content. Having created over 500+ pieces of financial content across reels, blogs, website posts and digital creatives, Kaashika helps audiences connect with the world of finance in a more accessible and engaging way.
